|
FLURBIPROFEN | |||
PRODUCT IDENTIFICATION |
|||
CAS NO. | 5104-49-4
(Racemic Mix) 51543-39-6 (S form) |
|
|
EINECS NO. | 225-827-6, 257-263-1 | ||
FORMULA | C15H13FO2 | ||
MOL WT. | 244.26 | ||
H.S. CODE |
|||
TOXICITY |
|
||
SYNONYMS | 3-Fluoro-4-phenylhydratropic acid; | ||
(±)-2-(2-fluoro-4 biphenylyl) propionic acid; (±)-2-Fluoro-a-methyl-4-biphenylacetic acid; | |||
SMILES |
|
||
CLASSIFICATION |
|||
PHYSICAL AND CHEMICAL PROPERTIES |
|||
PHYSICAL STATE | white to yellowish crystalline powder | ||
MELTING POINT | 114 - 117 C | ||
BOILING POINT |
|
||
SPECIFIC GRAVITY |
|
||
SOLUBILITY IN WATER | Slight soluble | ||
pH | |||
VAPOR DENSITY |
|
||
AUTOIGNITION |
|
||
NFPA RATINGS |
Health: 2 Flammability: 0 Reactivity: 0 | ||
REFRACTIVE INDEX |
|
||
FLASH POINT |
|
||
STABILITY |
Stable under ordinary conditions |
||
GENERAL DESCRIPTION & APPLICATIONS |
|||
Flurbiprofen, a derivative of phenylalkanoic acid, a nonsteroidal
anti-inflammatory agent; related to ibuprofen in structure; used in the
treatment of rheumatoid arthritis and osteoarthritis. It is applied topically to
the conjunctiva to inhibit miosis during ophthalmic surgery; administered
orally. It is a white to yellowish crystalline powder; slightly soluble in
water; soluble in most polar solvents. The chemical designation is
(±)-2-(2-fluoro-4 biphenylyl) propionic acid.
Nonsteroidal Antiinflammatory Drugs (NSAIDs); chemically heterogeneous large groups of drugs which suppress inflammation in a manner similar to steroids, but less side effects of sedation, respiratory depression, or addiction than steroids. They are widely used for the treatment of inflammatory disorders and painful conditions such as rheumatoid arthritis, gout, bursitis, painful menstruation, and headache. They are effective in the relief of pain and fever. NSAIDs inhibit the cyclooxygenase (COX) activity resulting in decreased synthesis of prostaglandin, leukotriene and thromboxane precursors such as the ubiquitous enzyme which catalyzes the initial step in the synthesis of prostanoids. Prostanoid is any of a group of C-20 fatty acids complex with an internal five or six carbon rings such as prostaglandins, prostanoic acid, prostacyclins, and thromboxane; derived from arachidonic acid (C-20 polyunsaturated fatty acid with four cis double bonds). The action or the synthesis of prostanoids are involved in the modulation of a variety of pathophysiologic processes including inflammation, hemostasis, thrombosis, cytoprotection, ulceration, hemodynamics and other the progression of kidney diseases. Thus, NSAIDs as non-selective inhibitors of the cyclooxygenases (both the cyclooxygenase-1 and cyclooxygenase-2 isoenzymes) may have beneficial as well as untoward effects on a variety of human diseases. Low stomach prostanoid levels caused by COX-1 inhibitors can result in ulceration and internal bleeding and perforation. The selective COX-2 inhibitors such as oxicam, meloxicam, and coxibs (celecoxib, rofecoxib, valdecoxib, parecoxib and etoricoxib) do not interfere with COX-1. The most prominent NSAID is aspirin. Nonaspirin NSAIDs can be classified based on chemical structures. Nonsteroidal Anti-Inflammatory Drugs (NSAID) by chemical structure
|
|||
SALES SPECIFICATION | |||
BIBLIOGRAPHY |
BP |
||
APPEARANCE |
White to yellowish crystalline powder | ||
ASSAY |
98.5
- 100.5%
|
||
HEAVY METALS |
10ppm
max
|
||
MELTING POINT |
114 - 117 C | ||
LOSS ON DRYING |
0.1% max |
||
TRANSPORTATION | |||
PACKING |
|
||
HAZARD CLASS | 6.1 (Packing Group: I) | ||
UN NO. | 2811 | ||
OTHER INFORMATION | |||
Hazard Symbols: XI, Risk Phrases: 23/24/25-36/37/38, Safety Phrases: 26-36/37/39-45 | |||
PRICE | |||
|
|